Voluntis’ Oleena Digital Application Receives FDA’s Marketing Approval to Self-Manage Cancer Symptoms

 Voluntis’ Oleena Digital Application Receives FDA’s Marketing Approval to Self-Manage Cancer Symptoms

Voluntis’ Oleena Digital Application Receives FDA’s Marketing Approval to Self-Manage Cancer Symptoms

Shots:

  • The US FDA has completed its regulatory review of Oleena software which is a Class II medical device facilitating oncology-related symptoms management and remote patient monitoring
  • Oleena is embedded with clinical algorithms offerings real-time personalized insights and actionable recommendations to the patients for managing their own symptoms while monitoring remote patients will improve clinical outcomes and minimizes the burden on health systems
  • Voluntis’ Oleena is the first prescription digital therapeutic in oncology transforming the patient’s experience through their cancer journey and is based on a software platform, Theraxium Oncology which is designed to allow data analytics and remote maintenance of digital therapeutics

Click here to­ read full press release/ article | Ref: Voluntis | Image: Digital Health London

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post